Genetically modified fungus stops malaria mosquitoes
A fungus that produces an insecticide can stop the spread of Anopheles mosquito, which causes malaria.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2175 entries already.
Entries by Thomas Gabrielczyk
Abacus Medicine postpones IPO
European pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment".
Make leukaemia therapy safer
A Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.
Nanobiotix spins out Curadigm
Cancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
Most expensive gene therapy globally approved
The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.
Chiesi acquires ex-US Raxone marketing rights
Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.
EU ministers set to exclude CRISPR crops from GMO legislation
EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.
Evotec acquires CDMO Just Biotherapeutics in US$90m deal
Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m.
AI improves protein manufacture
Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.
DNA Script raises US$38.5m in Series B round
In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.